Announcment!, page-194

Thanks mate, dilution here worries me a bit. The investment presentation didn't tell me much either in the way of their next upcoming Ann. However, I do feel that the idea behind this company will open it up to a lot of potential revenue streams. There's a lot of molecular targets that have been researched for breast and colon cancer, so effectively they're utilising previous knowledge to develop an effective prognostic tool. Think it's a good idea with a lot of potential merit. Also the management have a good name in science world.